Asymmetry Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Asymmetry Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-168,172	Closed	-$6.87M	–	30
2021 Q2	$6.87M	Sell	168,172 -119,318	-42%	-$4.64M	4.72%	9
2021 Q1	$11.6M	Buy	+287,490	New	+$15.6M	5.99%	3
2019 Q3	–	Sell	-22,500	Closed	-$1.09M	–	24
2019 Q2	$1.09M	Buy	+22,500	New	+$997K	0.59%	26

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Asymmetry Capital Management's ADPT Position: Q3 2021 in Review

Asymmetry Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 168,172 shares — an estimated $6.87M sold.

Asymmetry Capital Management first reported a position in ADPT in Q2 2019 and held it in 3 quarters. The position peaked at $11.6M in Q1 2021. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

Asymmetry Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
Asymmetry Capital Management sold 168,172 Adaptive Biotechnologies shares in Q3 2021, an estimated $6.87M.
Asymmetry Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 3 quarters.
Asymmetry Capital Management's Adaptive Biotechnologies position peaked at $11.6M in Q1 2021.
219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Asymmetry Capital Management's 13F filing for Q3 2021, filed 4 Nov 2021.